Endothelial Dysfunction in Cardiovascular Diseases and It’s Treatment

DOI

10.2991/978-94-6463-813-4_14How to use a DOI?

Keywords

Endothelial dysfunction; Nitric oxide; Atherosclerosis; Cardiovascular disease; Mechanism; Biomarkers

Abstract

Endothelial dysfunction is described by unbalanced dilation and constriction of blood vessel, elevated reactive oxygen species, and others factors, as well as low level of NO bioavailability. The presence of endothelial dysfunction breaks the barrier permeability that is a portion of inflammatory response in the progress of cardiovascular problems. Acquiring more knowledge into the pathophysiologic mechanisms that fervor atherosclerosis and endothelial dysfunction as well as discovering new biomarkers and treatment approaches to prevent atherosclerosis and endothelial dysfunction and lower the risk of developing CAD and its consequences are all areas of great interest. Novel markers of endothelial activity and dysfunction could have significant therapeutic ramifications. Adhesion molecules of endothelium, cytokines, some reactive proteins, selectin stimulates microparticles, perioxidation of low density lipoproteins, endocan etc. are biomarkers of endothelial activation. Endothelial healing can be achieved using pharmacological and nonpharmacological therapy. The former entails lowering body weight, engaging in cardiovascular activity, and limiting salt consumption; the latter involves the use of calcium antagonists, statins, erythropoietin, tetrahydrobiopterin, renin-angiotensin system inhibitors, and certain types of β blockers. These treatments aim to boost NO release and NO synthase activity, prevent NO degradation, and improve endothelial progenitor cell function.

Copyright

© 2025 The Author(s)

Open Access

Open Access This chapter is licensed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

Download article (PDF)

TY  - CONF
AU  - P. Khaliq Basha
AU  - A. Tejaswini
AU  - P. Nandini
AU  - P. Muni Sai
AU  - Goday Swapna
AU  - Y. Sarah Sujitha
PY  - 2025
DA  - 2025/08/13
TI  - Endothelial Dysfunction in Cardiovascular Diseases and It’s Treatment
BT  - Proceedings of the International symposium on Sustainable Drug Design and Nanoparticle development: Quantum and Computational Perspectives (SDDNDQCP 2025)
PB  - Atlantis Press
SP  - 191
EP  - 209
SN  - 2468-5739
UR  - https://doi.org/10.2991/978-94-6463-813-4_14
DO  - 10.2991/978-94-6463-813-4_14
ID  - Basha2025
ER  -